Clinical stage biopharmaceutical company developing novel drugs to treat heart failure, increasing contractility. The lead program AC01 is planned to enter phase 2 clinical development in 2022.
Location: Sweden, Solna kommun
Total raised: $22.56M
Investors 4
| Date | Name | Website |
| 08.09.2022 | Flerie Inv... | flerie.com |
| 02.10.2022 | Industrifo... | industrifo... |
| 29.03.2022 | Karolinska... | karolinska... |
| - | 3B Future ... | 3bfuturehe... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.01.2024 | Series A | $4.77M | - |
| 09.09.2022 | Series A | $14.21M | Industrifo... |
| 03.02.2022 | - | $3.58M | - |
Mentions in press and media 14
| Date | Title | Description | Source |
| 04.04.2024 | AnaCardio selected as finalist at the J.P. Morgan Asset Mana... | AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit ... | news.cisio... |
| 17.01.2024 | Karolinska Development’s portfolio company AnaCardio secures... | - | globenewsw... |
| 17.01.2024 | AnaCardio receives second tranche of SEK 50 million, complet... | AnaCardio receives second tranche of SEK 50 million, completing the previously announced Series A ro... | news.cisio... |
| 17.08.2023 | AnaCardio receives IND approval from the FDA for AC01 to Sta... | AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study Thu, Au... | news.cisio... |
| 13.04.2023 | AnaCardio reports first patient dosed in the GOAL-HF1 study,... | AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart F... | news.cisio... |
| 14.03.2023 | Ghrelin treatment in heart failure patients showed increased... | Ghrelin treatment in heart failure patients showed increased contractility of the heart Tue, Mar 14,... | news.cisio... |
| 17.11.2022 | AnaCardio Receives Regulatory Approval to Start a Phase 1b/2... | AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failure with A... | news.cisio... |
| 09.09.2022 | AnaCardio Raises Approx. USD14.21M in Series A Funding | AnaCardio, a Swedish clinical-stage biopharmaceutical company, completed a Series A funding round of... | finsmes.co... |
| 07.09.2022 | AnaCardio raises 150 million SEK in series A round co-led by... | Today we are happy to announce our investment in AnaCardio and are excited to support their importan... | industrifo... |
| 07.09.2022 | AnaCardio raises SEK 150 million to advance drug candidate A... | AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure Wed, Sep 07, 2022 0... | news.cisio... |
Show more